



## **United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.	
	09/671,658	09/27/00	GORMAN		D	15631-005920	
			HM12/1105	٦		EXAMINER	
	028008 DNAX RESEARCH INSTITUTE LEGAL DEPARTMENT 901 CALIFORNIA AVENUE PALO ALTO CA 94304				JAMROZ,M		
					ART UNIT	PAPER NUMBER	4
					1644		1,0
					DATE MAILED:	11/05/01	<i>V</i> •

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

		Application No.	Applicant(s)		
21.>- 21.>-		09/671,658	GORMAN ET AL.		
	Office Action Summary	Examiner	Art Unit		
	•	Margaret E Jamroz	1644		
Daried f	The MAILING DATE of this communication app	ears on the cover sheet with the	correspondence address		
A SH THE - Extrafte - If th - If N - Fail - Any	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).				
1)	Responsive to communication(s) filed on	·			
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b) ☐ Thi	is action is non-final.			
3)	Since this application is in condition for allowa closed in accordance with the practice under				
Disposi	tion of Claims		•		
4)[	Claim(s) <u>1-3 and 5-10</u> is/are pending in the ap	plication.			
	4a) Of the above claim(s) is/are withdraw	vn from consideration.			
	Claim(s) is/are allowed.				
	Claim(s) is/are rejected.				
7)[_	Claim(s) is/are objected to.		•		
8)	Claim(s) are subject to restriction and/or	r election requirement			
Applica	tion Papers		•		
	The specification is objected to by the Examine				
10)	The drawing(s) filed on is/are: a) ☐ accept	oted or b) objected to by the Ex	aminer.		
_	Applicant may not request that any objection to the				
11)	The proposed drawing correction filed on		roved by the Examiner.		
40\□	If approved, corrected drawings are required in rep				
,	The oath or declaration is objected to by the Ex	aminer.			
_	under 35 U.S.C. §§ 119 and 120		( ) ( )		
. —	Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 119	(a)-(d) or (t).		
а	) All b) Some * c) None of:	- h h			
	1. Certified copies of the priority document				
	2. Certified copies of the priority document	·			
*	3. Copies of the certified copies of the prior application from the International Bu See the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).	-		
14)⊠	Acknowledgment is made of a claim for domesti	ic priority under 35 U.S.C. § 119	e(e) (to a provisional application).		
	a) The translation of the foreign language pro Acknowledgment is made of a claim for domest				
Attachme	_		•		
2) 🔲 Not	tice of References Cited (PTO-892) tice of Draftsperson's Patent Drawing Review (PTO-948) ormation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Informa	ary (PTO-413) Paper No(s) al Patent Application (PTO-152) comply .		



Art Unit: 1644

## **DETAILED ACTION**

## Sequence Compliance

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is reminded to amend the specification (including the Brief Description of Drawings) and claims as appropriate to reflect compliance with the Sequence Rules.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Megan Jamroz, whose telephone number is (703) 308-8365. The examiner can normally be reached Monday to Friday from 8:00 to 4:30. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached at (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Margaret (Megan) Jamroz, Ph.D. Patent Examiner Technology Center 1600 November 1, 2001

PHUNK ANDER
PHILLIP GAMBEL, PH.D
PRIMARY EXAMINER
TOOL CONTON (600)

•	Application No.	Applicant(s)
Notice to Comply	09/671,658 Examiner	GORMAN ET AL.
	Margaret E Jamroz	1644

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide:  ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, including no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212